{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Biomarkers: FLT3-ITD positive, NPM1 positive, CEBPA. A \"good CR\" is defined as \\<5% blasts in the marrow by morphologic evaluation along with the absence of any MRD by flow cytometry or cytogenetics and recovery of blood counts (platelets \\>100,00 and absolute neutrophil count \\>1,000) by day 35 after induction. Cheson AML Response Criteria is used for Morphologic Leukemia Free State, Morphologic Complete Remission, Cytogenetic Complete Remission (CRc), Molecular Complete Remission (CRm), Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi), Partial Remission (PR), Treatment Failure, Recurrence (Progressive Disease).","groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"paramType":"NUMBER","populationDescription":"Participants with biomarkers: FLT3-ITD positive, NPM1 positive or CEBPA","reportingStatus":"POSTED","timeFrame":"38 days after dosing","title":"Number of Biomarker-positive Participants With Clinical Responses","type":"SECONDARY","unitOfMeasure":"participants with clinical responses"}